Kaveri Pohlman
Stock Analyst at Clear Street
(2.82)
# 1,753
Out of 5,152 analysts
30
Total ratings
35.48%
Success rate
3.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Downgrades: Hold | $32 → $12 | $13.97 | -14.10% | 3 | Jan 20, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $12 | $1.64 | +631.71% | 1 | Dec 30, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $61 → $99 | $59.70 | +65.83% | 1 | Dec 9, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $200 | $134.95 | +48.20% | 1 | Dec 5, 2025 | |
| JBIO Jade Biosciences | Initiates: Buy | $25 | $13.88 | +80.12% | 1 | Nov 25, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $11 → $21 | $13.08 | +60.55% | 1 | Nov 14, 2025 | |
| ZURA Zura Bio | Initiates: Buy | $18 | $6.76 | +166.27% | 1 | Nov 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $29 | $5.45 | +432.11% | 1 | Oct 22, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $46 | $33.17 | +38.68% | 1 | Sep 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $25.25 | +26.73% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.14 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $47 | $27.48 | +71.03% | 3 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $30 | $15.60 | +92.31% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $38 | $11.16 | +240.50% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $4.57 | +9.41% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.35 | +492.59% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $41.28 | -34.59% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $22.21 | +215.17% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $5.10 | +135.29% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $4.77 | +67.71% | 2 | Jul 7, 2022 |
Janux Therapeutics
Jan 20, 2026
Downgrades: Hold
Price Target: $32 → $12
Current: $13.97
Upside: -14.10%
Palisade Bio
Dec 30, 2025
Initiates: Buy
Price Target: $12
Current: $1.64
Upside: +631.71%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $61 → $99
Current: $59.70
Upside: +65.83%
Palvella Therapeutics
Dec 5, 2025
Initiates: Buy
Price Target: $200
Current: $134.95
Upside: +48.20%
Jade Biosciences
Nov 25, 2025
Initiates: Buy
Price Target: $25
Current: $13.88
Upside: +80.12%
Trevi Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $11 → $21
Current: $13.08
Upside: +60.55%
Zura Bio
Nov 13, 2025
Initiates: Buy
Price Target: $18
Current: $6.76
Upside: +166.27%
Sagimet Biosciences
Oct 22, 2025
Initiates: Buy
Price Target: $29
Current: $5.45
Upside: +432.11%
Oruka Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $33.17
Upside: +38.68%
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $25.25
Upside: +26.73%
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.14
Upside: -
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $27.48
Upside: +71.03%
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $15.60
Upside: +92.31%
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $11.16
Upside: +240.50%
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $4.57
Upside: +9.41%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $1.35
Upside: +492.59%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $41.28
Upside: -34.59%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $22.21
Upside: +215.17%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $5.10
Upside: +135.29%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $4.77
Upside: +67.71%